For her visionary leadership in the biotechnology and philanthropic sectors
Montreal-born Lady Mireille Gillings, PhD, Hon DSc, is a visionary leader with more than 25 years of proven scientific, clinical and operational expertise and leadership in the biopharmaceutical industry.
Lady Mireille Gillings founded and grew HUYABIO International to be the leader in accelerating the advancement of novel biopharmaceutical product opportunities originating in China. This work has enabled faster, more cost-effective, lower-risk drug development in global markets. Through this model, Hiyasta, an immuno-oncology drug, was successfully launched in Japan. She has also made significant contributions to neurological and neurodegenerative disease research, with a focus on neuroactive steroids.
Lady Mireille Gillings was appointed to the Board of Quintiles, now IQVIA, a Fortune 500 company, and serves on the Pasteur Institute advisory board. She financially co-founded GHO Capital, a European private-equity fund specializing in global health opportunities, where she serves as vice-chair. Personal passions include the Gillings School of Global Public Health and building international scientific partnerships through the Mireille and Dennis Gillings Global Public Health Fellowships with the aim to develop the next generation of public health leaders.
Among the many honours received by this Concordia graduate, the Government of France conferred upon Lady Mireille Gillings its highest award, the Legion of Honour, for her contributions to neuroscience and entrepreneurship. She has an honorary degree from the University of Exeter and has twice been named one of the top women entrepreneurs by the Sunday Times in the United Kingdom. Lady Mireille Gillings holds a PhD in Neuroscience from Radboud University, Nijmegen and post-doctoral fellowships at Bordeaux University and Scripps Institute.